Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics (IOVA) pioneers tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers, leading the next generation of personalized immunotherapies. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely announcements including FDA submissions, clinical trial data publications, manufacturing advancements, and partnership agreements. Our curated collection ensures you stay informed about IOVA developments impacting oncology treatment paradigms and biopharmaceutical innovation.
Key updates cover therapy approvals, research collaborations, financial results, and scientific presentations. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Iovance's latest progress in developing TIL-based therapies for melanoma, cervical cancer, and other solid tumors. Regularly updated to serve as your definitive resource for IOVA-related news analysis.
Iovance Biotherapeutics announced a definitive agreement to acquire global rights to Proleukin® (aldesleukin) for £166.7 million, enhancing T-cell therapies for cancer treatment. The acquisition is projected to generate immediate and future revenue while securing the IL-2 supply chain. With an unaudited cash position of approximately $477 million, the company is well-positioned financially until 2024. Additionally, positive FDA feedback was received for the Phase 3 TILVANCE-301 trial in advanced melanoma, expected to randomize 670 patients. Lifileucel showed a 47% objective response rate in NSCLC trials, with ongoing enrollment.
Iovance Biotherapeutics announced its participation in key upcoming conferences aimed at highlighting its innovative T cell-based cancer therapies. The company will present at the Piper Sandler Healthcare Conference on November 30, 2022, followed by the JMP Securities Summit on December 7, 2022, and the J.P. Morgan Healthcare Conference on January 11, 2023. Iovance's lead product, lifileucel, is a pioneering treatment for metastatic melanoma and aims to be the first approved one-time cell therapy for solid tumors. Webcasts of these events will be accessible on their investor relations website.
Iovance Biotherapeutics (NASDAQ: IOVA) announced that its rolling Biologics License Application (BLA) for lifileucel is expected to conclude in Q1 2023. The FDA has provided crucial feedback on the investigational new drug application, which the company will address promptly. Lifileucel, aimed at treating advanced melanoma, currently has no FDA-approved therapy in its category. A successful pre-BLA meeting and ongoing clinical trials further support its potential approval, as Iovance strives to deliver the first individualized cell therapy for this patient group.
Iovance Biotherapeutics announced promising results from its C-144-01 trial for lifileucel, a TIL therapy for advanced melanoma. The trial, featuring 153 patients, reported a 31% objective response rate (ORR) with ongoing responses and a median duration of response not reached at 27.6 months. Median overall survival was 13.9 months. The company is on track to submit a rolling BLA to the FDA by year-end 2022. These results highlight the potential of lifileucel as a significant treatment option in a market currently lacking approved therapies for this patient group.
Iovance Biotherapeutics (NASDAQ: IOVA) initiated a rolling Biologics License Application (BLA) for lifileucel in advanced melanoma, expected to complete in Q4 2022. The company reported a net loss of $99.6 million for Q3 2022, up from $86.1 million in Q3 2021, with R&D expenses rising by 11% to $72.5 million. Their cash position stands at $366.6 million, enough to fund operations into 2024. Iovance aims for FDA approval and commercial launch in 2023, supported by advancements in clinical trials and manufacturing capabilities.
Iovance Biotherapeutics (NASDAQ: IOVA) will announce its Q3 financial results on November 3, 2022. A conference call and live audio webcast will be held at 4:30 p.m. ET for a detailed review and corporate update. Iovance is focused on pioneering T cell-based cancer immunotherapies, specifically targeting metastatic melanoma with its lead candidate, lifileucel, which aims to be the first approved one-time cell therapy for solid tumors. The archived webcast will be available for one year post-event.
Iovance Biotherapeutics has initiated the IOV-GM1-201 trial, marking a key step in developing its genetically modified TIL therapy, IOV-4001, targeting metastatic non-small cell lung cancer and advanced melanoma. The trial is a first-in-human study assessing the therapy's safety and efficacy. The innovative approach involves TALEN® gene editing to inactivate PD-1, aiming to enhance anti-tumor activity. The trial is currently enrolling participants, indicating potential advancements in cancer treatment options.
Iovance Biotherapeutics announced oral and poster presentations for the C-144-01 trial at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting on November 10, 2022. The presentations cover the lifileucel TIL cell monotherapy for advanced melanoma and a Phase 1/2 study of TALEN-mediated PD-1–inactivated TILs in melanoma and NSCLC. A conference call will discuss the pooled analysis of the trial's cohorts. With a focus on advancing TIL therapies, Iovance aims to innovate cancer treatment.
Iovance Biotherapeutics, a late-stage biotechnology company focused on cancer immunotherapy, plans to present at several key conferences in September. These include the Wells Fargo Healthcare Conference on September 7, HC Wainwright Annual Global Investment Conference starting September 12, Baird Global Healthcare Conference on September 13, and the Cantor Oncology Conference on September 28. The events will feature discussions about their lead product candidate, lifileucel, which aims to be the first approved one-time cell therapy for solid tumors. Webcasts will be available online.
Iovance Biotherapeutics (NASDAQ: IOVA) announced the publication of clinical data and trial designs for its tumor infiltrating lymphocyte (TIL) therapies at the ESMO Congress 2022 in Paris, from September 9-13, 2022. Two key abstracts were presented: Abstract #844P on the efficacy of lifileucel in advanced melanoma and Abstract #883TiP detailing a study on PD-1 inactivated TIL. These advances are part of Iovance's commitment to developing TIL therapies aimed at transforming cancer treatment.